Zobrazeno 1 - 10
of 681
pro vyhledávání: '"Yoon Koo Kang"'
Autor:
Yoon-Koo Kang1 ykkang@amc.seoul.kr, Min-Hee Ryu1, Yong Sang Hong1, Chang-Min Choi1, Tae Won Kim1, Baek-Yeol Ryoo1, Jeong Eun Kim1, Weis, John R.2, Kingsford, Rachel2, Cheol Hee Park3, Seong Jang3, McGinn, Arlo3, Werner, Theresa L.2, Sharma, Sunil4
Publikováno v:
Cancer Research & Treatment. Jul2024, Vol. 56 Issue 3, p743-750. 8p.
Autor:
Jean-Yves Blay, Antoine Italiano, Stephane Champiat, Paolo Antonio Ascierto, Manish Sharma, Jeeyun Lee, Luis Paz-Ares Rodriguez, Keun-Wook Lee, Yoon-Koo Kang, Drew Rasco, Edith A Perez, Mariano Ponz-Sarvise, Lu Xu, Jean-Philippe Spano, Coya Tapia, Ecaterina Dumbrava, Kathleen Moore, Jason Ptacek, Michele Magni, Alfonso Cortes Salgado, Ming Yin, Agnese Losurdo, Antoine Deleuze, Mark D Pegram, Ardaman Shergill, Alexander I Spira, Michael N Alonso, Joan Albanell Mestres, Marta GilMartin, Arielle Heeke, Ana Oaknin Benzaquen, Ignacio Ortego Zabalza, Haeseong Park, Cecile Vicier, Ivan Victoria, Benjamin Weinberg, Bob T Li
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/879b533d48f5495a9fe68f7bb2c1bccc
Autor:
Min‐Hee Ryu, Kyung Hee Lee, Lin Shen, Kun‐Huei Yeh, Changhoon Yoo, Young Seon Hong, Young Iee Park, Sung Hyun Yang, Dong Bok Shin, Dae Young Zang, Won Ki Kang, Ik‐Joo Chung, Yeul Hong Kim, Baek‐Yeol Ryoo, Byung‐Ho Nam, Young Soo Park, Yoon‐Koo Kang
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 7784-7794 (2023)
Abstract Background In this randomized phase II study, we evaluated the efficacy and safety of sorafenib in combination with capecitabine and cisplatin (XP) as first‐line chemotherapy in advanced gastric cancer. Patients and Methods Patients with m
Externí odkaz:
https://doaj.org/article/282b0a8fa02d4899b6eff2f3eaf72e70
Autor:
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, Katrin M. Sjoquist, Andrew J. Martin, Sonia Yip, Yoon-Koo Kang, Yung-Jue Bang, Li-Tzong Chen, Markus Moehler, Tanios Bekaii-Saab, Thierry Alcindor, Christopher J. O’Callaghan, Niall C. Tebbutt, Wendy Hague, Howard Chan, Sun Young Rha, Keun-Wook Lee, Val Gebski, Anthony Jaworski, John Zalcberg, Timothy Price, John Simes, David Goldstein
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Advanced gastro-oesophageal cancer (AGOC) carries a poor prognosis. No standard of care treatment options are available after first and second-line therapies. Regorafenib is an oral multi-targeted tyrosine kinase inhibitor targeti
Externí odkaz:
https://doaj.org/article/b8e8b11dcadf410b83fe55a98f0861f4
Autor:
Stephen L. Chan, Martin Schuler, Yoon-Koo Kang, Chia-Jui Yen, Julien Edeline, Su Pin Choo, Chia-Chi Lin, Takuji Okusaka, Karl-Heinz Weiss, Teresa Macarulla, Stéphane Cattan, Jean-Frederic Blanc, Kyung-Hun Lee, Michela Maur, Shubham Pant, Masatoshi Kudo, Eric Assenat, Andrew X. Zhu, Thomas Yau, Ho Yeong Lim, Jordi Bruix, Andreas Geier, Carmen Guillén-Ponce, Angelica Fasolo, Richard S. Finn, Jia Fan, Arndt Vogel, Shukui Qin, Markus Riester, Vasiliki Katsanou, Monica Chaudhari, Tomoyuki Kakizume, Yi Gu, Diana Graus Porta, Andrea Myers, Jean-Pierre Delord
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-19 (2022)
Abstract Background Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclin
Externí odkaz:
https://doaj.org/article/1a80d93b46254b83bfdf5d4c0de1a368
Autor:
Jwa Hoon Kim, Min-Hee Ryu, Young Soo Park, Jungeun Ma, Sun Young Lee, Deokhoon Kim, Yoon-Koo Kang
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Purpose The phase 3 ATTRACTION-2 study demonstrated that nivolumab monotherapy improved survival compared to placebo in patients with pretreated advanced gastric cancer (AGC). However, the efficacy of nivolumab seems to be limited to a subse
Externí odkaz:
https://doaj.org/article/117f4e5f9eca4a12be4b7d26d19b31e8
Autor:
Narikazu Boku, Amit Roy, Yan Feng, Paul Nghiem, Yoon-Koo Kang, Martin Reck, Li-Tzong Chen, Taofeek K Owonikoko, Hye Ryun Kim, Ming Lei, Gregory Plautz, Han Chang, Wen Hong Lin, Akintunde Bello, Jennifer Sheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/676c1e6d78204c7e80157d5c02b8b264
Autor:
Chia-Jui Yen, Masatoshi Kudo, Ho-Yeong Lim, Chih-Hung Hsu, Arndt Vogel, Giovanni Brandi, Rebecca Cheng, Ioana Simona Nitu, Paolo Abada, Yanzhi Hsu, Andrew X. Zhu, Yoon-Koo Kang
Publikováno v:
Liver Cancer, Pp 1-15 (2020)
Objective: REACH-2 and REACH were randomized, placebo-controlled, double-blind, multicenter phase 3 trials which showed survival benefits of ramucirumab treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein
Externí odkaz:
https://doaj.org/article/56325c9739d2463abfb71dbe7e992f0a
Autor:
Ulrich T. Hacker, Dirk Hasenclever, Nicolas Linder, Gertraud Stocker, Hyun‐Cheol Chung, Yoon‐Koo Kang, Markus Moehler, Harald Busse, Florian Lordick
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 11, Iss 1, Pp 135-144 (2020)
Abstract Background Body fat and/or muscle composition influences prognosis in several cancer types. For advanced gastric and gastroesophageal junction cancer, we investigated which body composition parameters carry prognostic information beyond well
Externí odkaz:
https://doaj.org/article/2022d846a371467cbc1247d80ce6e73f
Autor:
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Manish A Shah, Eric Van Cutsem, Rui-Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon-Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Jung Wook Park, Mok Oh, Jaffer A Ajani
Publikováno v:
The Lancet. 401:1655-1668